Skip to Content

IMGN529 FDA Approval Status

FDA Approved: No
Brand name: IMGN529
Company: ImmunoGen, Inc.
Treatment for: Non-Hodgkin's Lymphoma

IMGN529 is a CD37-targeting Antibody-Drug Conjugate (ADC) in development for the treatment of non-Hodgkin's Lymphoma and other B-cell malignancies.

Development Timeline for IMGN529

DateArticle
Sep 23, 2011ImmunoGen, Inc. Announces Submission of IND for Wholly Owned Product Candidate for Non-Hodgkin's Lymphoma

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.